Dr Marc Machaalani talks to ecancer at ESMO 2024 about the poster he presented at ESMO 2024.

Fam-trastuzumab deruxtecan-nxki has been granted accelerated approval for patients with any advanced HER2-positive cancer.

Since ERBB2 amplification status is concordant with HER2 overexpression and IHC positivity the researchers sought to examine the distribution of ERBB2 amplifications across sex, race, and cancer type subgroups in a large dataset.

This study included 103,786 patients with genomic tumour profiling data in the AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) registry.

It illustrated differences in the distribution of ERBB2 amplifications which may guide treatment selection with HER2-directed therapies.